Amesergide

Amesergide
Clinical data
Other names	LY-237733; N-Cyclohexyl-11-isopropyllysergamide
Routes of; administration	By mouth
Identifiers
	IUPAC name (6aR,9R,10aR)-N-Cyclohexyl-7-methyl-4-propan-2-yl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxamide;
CAS Number	121588-75-8;
PubChem CID	9821951;
ChemSpider	7997700;
UNII	EJL329H95R;
KEGG	D02893;
ChEMBL	ChEMBL160293;
CompTox Dashboard (EPA)	DTXSID8052851 ;
Chemical and physical data
Formula	C25H35N3O
Molar mass	393.575 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)N1C=C2C[C@@H]3[C@H](C[C@H](CN3C)C(=O)NC4CCCCC4)C5=C2C1=CC=C5;
	InChI InChI=1S/C25H35N3O/c1-16(2)28-15-17-13-23-21(20-10-7-11-22(28)24(17)20)12-18(14-27(23)3)25(29)26-19-8-5-4-6-9-19/h7,10-11,15-16,18-19,21,23H,4-6,8-9,12-14H2,1-3H3,(H,26,29)/t18-,21-,23-/m1/s1; Key:KEMOOQHMCGCZKH-JMUQELJHSA-N;

Amesergide (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name LY-237733) is a serotonin receptor antagonist of the ergoline and lysergamide families related to methysergide which was under development by Eli Lilly and Company for the treatment of a variety of conditions including depression, anxiety, schizophrenia, male sexual dysfunction, migraine, and thrombosis but was never marketed. It reached phase II clinical trials for the treatment of depression, erectile dysfunction, and premature ejaculation prior to the discontinuation of its development.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.